TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Knowledge of technical skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time to Initiation of Temperature Management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: USP (Urinary Symptoms Profile) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: End-stage Renal Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Functional assessment of dentures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Surface Disease Index (OSDI©) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Alveolar bone remodeling - horizontal measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Alveolar bone remodeling - vertical measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Blood-plasma concentration of Piperacillin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Facial Inflammatory Acne-related Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fetal cord blood Tumor Necrosis Factor-Alfa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fetal cord blood Interleukin-6 cytokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum creatinine level 2 weeks after nephrostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum BUN level 2 weeks after nephrostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: RRF in DMSA 2 weeks after nephrostomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: AUC (Area under the plasma concentration time curve) of ethinyl estradiol/norethindrone (EE/NET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum observed concentration) of EE/NET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCss (Area under the concentration time curve at steady state) of nevirapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing performance status scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetration aspiration scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Migration of prosthesis components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of Stroke Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Accuracy of Cardiac Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frontal lobe cerebral oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Foetal heartrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Bacterial flora on the Baha abutment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Presence of significant qEEG hypoglycaemia indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and salivary 8-OHdG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of all assessments and visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anxiety prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life scale assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in upper motor strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of EPC cells per microliter of blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of defecation per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Time to Itch Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total consumption of FVIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bleedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall assessment by the physician
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in bilirubin to less than 75% of the pretreatment value within 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early cholangitis occurring within 48 hours to 7 days of the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Histologic Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of total satisfying sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: optimal Ce of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: AUC0-t of salicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of salicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of salicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade III/IV GVHD incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Total Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neurodevelopment (Bayley Scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurological Evaluation (GMFM-88 Scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of PBMC cells count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in Range (70-180 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hematoma Reduced Amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline language performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Lymphoedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Change in gut bacterial composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HDL, LDL, total cholesterol and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of thrombotic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary target lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Drug-induced upper gastrointestinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Respond time in visual search
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of Maintenance of Erection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Freedom from any atrial arrhythmia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Durable Engraftment (Presence of Donor Cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage change in partial seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: E-cig Use at End of Sampling Period
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerance of the systems set up and use frequency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin prick test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Methacholine provocation of the pulmonary system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate and extent of absorption of d-amphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reoperation due to epidural hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Hydromorphone usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Ratio of Degranulated Goblet Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for PF-04965842
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-04965842
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) for PF-06471658 (M1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06471658 (M1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of worsening of PAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean Absolute Relative Difference (MARD) Between BGMS Results and Reference Method Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Measurement of depression status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of Posterior Capsule Opacification (PCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Basal Insulin Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Kingston Caregiver Stress Scale (KCSS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Patient Health Questionnaire - 9 (PHQ-9) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of adequately placed patches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Cidal Activity (Log Inhibition of Growth)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and specificity of bi-target stool DNA testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of bi-target stool DNA testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative predictive value of bi-target stool DNA testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of sensor glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in heart rate and/or systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Strain-specific hemagglutination inhibition (HAI) antibody seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: acute and chronic radiation injury incidence of vagina
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Interaction of the Serotonin Receptor and 5-HT2AR Antagonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with cGVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Balance Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body fat mass in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lean body mass in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the number of patients with positive microbiological results for C. acnes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUCt of Varenicline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Varenicline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of specific phenolics and their metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in strength of core muscle groups (trunk) at 12-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in strength of core muscle groups (hip) at 12-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in endurance of core muscle groups at 12-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in flexibility of the lower back and hamstring muscles at 12-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in ability of the dynamic balance at 12-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of 131I-8H9
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic parameters of EACA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant Shoulder Score (CSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Number of Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Number of Drinks per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Number of Binge Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rejection of novel food
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Subjects With Adverse Effects After a Single Dose of VBP15
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) After a Single Dose of VBP15 (0 Through 72 Hours Post Dose)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of VBP15 After a Single Dose of VBP15
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiological healing of simple bone cyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Delayed graft function (DGF) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: HIV seroconversion rate
Endpoint domain: Mortality/survival
Primary endpoint: size of the obtained pleural biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depth of the obtained pleural biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: integrity of the obtained pleural biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rescue-free laxation response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean change in average daily intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Regression Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of Life related to sleep
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants With >=50% Improvement From Baseline in Clinical Global Impression for Bipolar Disorders Overall Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Global Impression for Bipolar Disorders Overall Severity Remission (Score <=2 at Week 8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Uptake value of 18F-FDOPA PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement rate for transition program components
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change from Baseline hemoglobin a1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline diabetes management functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: change in hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Lens Centration Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Corneal Coverage Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Primary RF wire success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Schistosomiasis reinfection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lower back pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial Emotion Identification
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Facial Emotion Discrimination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants Who Developed Nephrogenic Systemic Fibrosis (NSF)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Clinical Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Respiratory Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Breath odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative FLACC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative sedation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well-being as assessed by the WHO-5
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of women eligible for the trial
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Compliance with trial procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to a Sexual Agreement at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Feasibility of the training
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number Who Reached a Safe Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Renal Function as Measured by 24 Hour Urine Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function as Measured by Serum Creatinine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function as Measured by Cockcroft Gault Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function as Measured by Modification of Diet in Renal Disease (MDRD) Estimated Glomerular Filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function as Measured by Iothalamate Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: initial liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP-9 levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymphocyte levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants with identifiable brain lesions detected by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes